Dual Antiplatelet Therapy with Clopidogrel and Aspirin Versus Aspirin Monotherapy in Patients Undergoing Coronary Artery Bypass Graft Surgery.
Jianyu Qu,Heng Zhang,Chenfei Rao,Sipeng Chen,Yan Zhao,Hansong Sun,Yunhu Song,Sheng Liu,Liqing Wang,Wei Feng,Shuiyun Wang,Shengshou Hu,Zhe Zheng
DOI: https://doi.org/10.1161/jaha.120.020413
IF: 6.106
2021-05-20
Journal of the American Heart Association
Abstract:Background The optimal antiplatelet therapy after coronary artery bypass grafting remains unclear. We evaluated the association of dual antiplatelet therapy (DAPT) with clopidogrel plus aspirin and clinical outcomes among patients undergoing coronary artery bypass grafting. Methods and Results A total of 18 069 consecutive patients who underwent primary isolated coronary artery bypass grafting between 2013 and 2017 were identified from a contemporary registry, and 10 854 (60.1%) received DAPT with clopidogrel plus aspirin as determined by claimed prescriptions after surgery. Cox regression models with inverse probability of treatment weighting were used to examine the associations between DAPT and outcomes. Patients who received DAPT, compared with those who received aspirin monotherapy, had a lower incidence of a composite of all‐cause death, myocardial infarction, stroke, or repeat revascularization at 6 months (2.9% versus 4.2%; inverse probability of treatment weighting–adjusted hazard ratio [HR], 0.65; 95% CI, 0.55–0.77; P <0.001) as well as death (HR, 0.61; 95% CI, 0.41–0.90), myocardial infarction (HR, 0.55; 95% CI, 0.40–0.74), and stroke (HR, 0.58; 95% CI, 0.46–0.74). The incidence of major bleeding did not differ significantly between the 2 groups (HR, 1.11; 95% CI, 0.69–1.78). Similar results were noted across multiple subgroups as well as when using different analytic methods. Conclusions Among patients undergoing coronary artery bypass grafting, DAPT with clopidogrel plus aspirin as secondary prevention was associated with reduced risk of major adverse cardiovascular and cerebrovascular events within 6 months as compared with aspirin monotherapy, and there was no significant increase in major bleeding. Nonstandard Abbreviations and Acronyms DAPT dual antiplatelet therapy IPTW inverse probability of treatment weighting MACCE major adverse cardiac and cerebrovascular events Clinical Perspective What Is New? The present study is one of the largest analyses that primarily focused on the association of dual antiplatelet therapy and major outcomes in patients who underwent coronary artery bypass grafting. We found that post–coronary artery bypass grafting dual antiplatelet therapy with clopidogrel plus aspirin was associated with reduced risk of major adverse cardiovascular and cerebrovascular events within 6 months as compared with aspirin monotherapy, and there was no significant increase in major bleeding. The association of dual antiplatelet therapy with fewer clinical events was consistent across key clinical subgroups, including age, sex, clinical presentations, diabetes mellitus, and bypass techniques. What Are the Clinical Implications? Dual antiplatelet therapy with clopidogrel plus aspirin could be a promising secondary prevention strategy that may improve the outcome of patients who had coronary artery bypass grafting, including those with acute coronary syndrome or stable angina, presence or absence of diabetes mellitus, or had on‐pump or off‐pump bypass. Coronary artery bypass grafting (CABG) has been established as an effective treatment for patients with extensive coronary artery disease. 1 Aspirin is recommended as a fundamental secondary prevention medication for patients with CABG to maintain the benefits of revascularization and prevent major adverse cardiovascular events. 2 However, patients treated with CABG still have a notable risk of subsequent major ischemic cardiac and cerebrovascular events, which may exceed 10% in the first 6 to 12 months after the surgery. 3 Reduced postoperative responsiveness to aspirin, platelet activation, and thrombosis results in systemic hypercoagulability and early graft failure. These have been identified as vital contributing factors in this context. 4 , 5 , 6 , <a class="tab-link" href="#jah36226-bib-00 -Abstract Truncated-
cardiac & cardiovascular systems